Erosive polyarticular chronic tophaceous gout Regional Winner of East Asia and Pacific Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/1wrNAhjsw6

Juvenile dermatomyositis, with Gottren's and diffuse hyperpigmentation Regional Winner of Europe & Central Asia Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/vxayxgINa8

Lichenoid cutaneous lupus erythematosus mimicking acanthosis nigricans Regional Winner of Latin America and Caribbean Image Competition: Rheum Dz in Patients of Color #ACR21 @rheumnow https://t.co/4oAXIClwsm

#ACR21 Abst#0453. KEEPsAKE: Risankizumab (Skyrizi) monoclonal Ab inhibits IL23 by binding p19. ▶️150 mg RZB vs Placebo ⭐️RZB: higher ACR20/50/70, PASI90, HAQ-DI ⭐️Resolution of enthesitis, dactylitis. Improve fatigue, fxn ⭐️No safety signal https://t.co/bqQJ4Zr7o5 @Rheumnow https://t.co/2ZfGRs2GUd

#SLE pts have equal rates of post op CV events compared to TypeII DM pts and ⬆️ compared to matched controls. Esp driven by comorbidities. Should we add ASA post op in SLE pts with CV risks? #ACR21 #abst0128 @RheumNow https://t.co/COdbDxFgBQ

Rare co-existence of FMF & axSpA significantly lowered age of axSpA symptom onset. Radiographic changes in FMF+axSpA suggested worse disease. Rate of amyloidosis and hip involvement were higher in FMF+axSpA pts. Abs 0378 #ACR21 #RheumNow @RheumNow https://t.co/lUmn3A90Ob https://t.co/n3kj8GcV1i

KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA: 👉phase 3 DBRPCT 24 weeks 👉150 mg week 0,4, 16 weeks 👉improved ACR20,ACR50,ACR70 👉improved PASI90 👉improved HAQ-DI 👉no increased safety signals #ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/ioIBXgV4Hi

Abs 0463 #ACR21 @RheumNow Park & colleagues compared treatment persistence across abatacept, TNFi, and JAKi in dual seropositive RA patients using Medicare database - Users of abatacept were more persistent to index time of 12 months and showed longer time to discontinuation https://t.co/0huE7zZjLq

#ACR21 Abst#0454 Lupus nephritis mortality from 1999-2019 ⭐️-27% age-standardized mortality rate in LN death, though increased trend in last 5 yrs! ▶️ Afr-American 38% of deaths, though 12% of population (RR ~4.5), ⬆️mortality with urbanization https://t.co/fjeGXtItvD @RheumNow https://t.co/cE3t6lq8zi

Promising results of Risankizumab for #psoriaticarthritis 🔸Pts significantly achieved higher rates of ACR20, 50 and 70 response at wk 24 vs. placebo 🔸Well tolerated and showed no safety signals @RheumNow #ACR21 #ACRBest abs0453 https://t.co/TDSLEgF68g

#ACR21 @RheumNow Abst#0450 Hwang et al. from the PSOAS cohort analyzed 1618 radiographs between 2002-2017 ⭐️Higher spinal disease: Male gender; longer disease duration; smoking ⭐️🔼Disease progression 🔼CRP levels ⭐️🔽Disease progression with time-varying TNFI use https://t.co/XsKp28HOxz